We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
-1.4%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$45.6B
AUM Growth
-$2.97B
Cap. Flow
-$1.56B
Cap. Flow %
-3.42%
Top 10 Hldgs %
10.17%
Holding
4,085
New
718
Increased
950
Reduced
874
Closed
814

Top Buys

Rank Stock Value
1
JPM icon
JPMorgan Chase
JPM
+$352M
2
KR icon
Kroger
KR
+$279M
3
T icon
AT&T
T
+$235M
4
INTC icon
Intel
INTC
+$217M
5
EW icon
Edwards Lifesciences
EW
+$212M

Sector Composition

Rank Sector Weight
1 Financials 19.08%
2 Technology 16.14%
3 Healthcare 15.45%
4 Consumer Discretionary 9.74%
5 Consumer Staples 5.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VRA icon
2926
Vera Bradley
VRA
$104M
$299K ﹤0.01%
+99,601
New +$401K
MBIN icon
2927
Merchants Bancorp
MBIN
$2.24B
$298K ﹤0.01%
+12,949
New +$332K
ONMD icon
2928
OneMedNet
ONMD
$40.4M
$298K ﹤0.01%
28,754
ZLAB icon
2929
Zai Lab
ZLAB
$2.1B
$298K ﹤0.01%
8,710
-50,597
-85% -$2.16M
CRNT icon
2930
Ceragon Networks
CRNT
$195M
$296K ﹤0.01%
160,838
+118,238
+278% +$281K
IAT icon
2931
iShares US Regional Banks ETF
IAT
$682M
$296K ﹤0.01%
+6,200
New +$322K
YMAB
2932
DELISTED
Y-mAbs Therapeutics
YMAB
$295K ﹤0.01%
+20,470
New +$339K
CCSI icon
2933
Consensus Cloud Solutions
CCSI
$683M
$294K ﹤0.01%
+6,200
New +$319K
CHRS icon
2934
Coherus Oncology
CHRS
$222M
$294K ﹤0.01%
+30,534
New +$309K
LAKE icon
2935
Lakeland Industries
LAKE
$106M
$291K ﹤0.01%
+25,188
New +$359K
MVST icon
2936
Microvast
MVST
$256M
$291K ﹤0.01%
+160,389
New +$383K
ATRA icon
2937
Atara Biotherapeutics
ATRA
$70.4M
$290K ﹤0.01%
+3,064
New +$344K
TOIIW
2938
CALL
The Oncology Institute Warrant
TOIIW
$4.36M
$290K ﹤0.01%
62,506
+14
+0% +$10
CGBD icon
2939
Carlyle Secured Lending
CGBD
$719M
$289K ﹤0.01%
25,300
-63,827
-72% -$866K
DEO icon
2940
Diageo
DEO
$49.4B
$289K ﹤0.01%
+1,700
New +$305K
SRAD icon
2941
Sportradar
SRAD
$4.38B
$288K ﹤0.01%
32,682
-94,640
-74% -$943K
VTI icon
2942
CALL
Vanguard Total Stock Market ETF
VTI
$656B
$288K ﹤0.01%
+1,600
New +$319K
BNL icon
2943
Broadstone Net Lease
BNL
$4.3B
$287K ﹤0.01%
+18,486
New +$375K
FPAY
2944
DELISTED
FlexShopper
FPAY
$287K ﹤0.01%
+154,517
New +$261K
GSRMR
2945
CALL
DELISTED
GSR II Meteora Acquisition Corp. Right
GSRMR
$287K ﹤0.01%
28,797
FCG icon
2946
First Trust Natural Gas ETF
FCG
$609M
$286K ﹤0.01%
+12,500
New +$302K
SNPE icon
2947
Xtrackers S&P 500 ESG ETF
SNPE
$2.58B
$285K ﹤0.01%
+8,900
New +$319K
MIST icon
2948
Milestone Pharmaceuticals
MIST
$133M
$284K ﹤0.01%
+30,898
New +$234K
NOGNW
2949
CALL
DELISTED
Nogin, Inc. Warrant
NOGNW
$284K ﹤0.01%
209,910
-400
-0.2% -$84
MUB icon
2950
iShares National Muni Bond ETF
MUB
$45.3B
$283K ﹤0.01%
2,760
-8,500
-75% -$904K

Similar funds

Marshall Wace's Q3 2022 Portfolio in Review

As of Q3 2022, Marshall Wace held 4,085 positions worth $45.6B, down 6.1% from $48.6B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace withdrew a net $1.56B in Q3 2022, closing 814 positions and reducing 874 holdings. Its most notable exit was General Dynamics, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Marshall Wace opened a new position in Albertsons Companies worth $84.6M.

  • Marshall Wace's largest Q3 2022 buy was Albertsons Companies: 3,404,097 shares worth $84.6M.
  • Marshall Wace added most to JPMorgan Chase in Q3 2022, an estimated $352M increase.
  • Marshall Wace's biggest Q3 2022 reduction was UnitedHealth, cutting an estimated $461M.
  • Marshall Wace fully exited General Dynamics in Q3 2022, selling an estimated $122M.
  • Marshall Wace's ten largest holdings make up 10% of its $45.6B portfolio in Q3 2022.
  • Marshall Wace opened 718 new positions and closed 814 in Q3 2022.
  • Marshall Wace's portfolio value fell 6.1% quarter-over-quarter to $45.6B.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.